Tyra Biosciences (TYRA) Competitors $12.50 -0.29 (-2.27%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$12.75 +0.25 (+1.99%) As of 09/19/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TYRA vs. KNSA, GMTX, CGON, ALVO, CPRX, TARS, IDYA, OCUL, MLYS, and IBRXShould you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Mineralys Therapeutics (MLYS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. Tyra Biosciences vs. Its Competitors Kiniksa Pharmaceuticals International Gemini Therapeutics CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Mineralys Therapeutics ImmunityBio Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Is KNSA or TYRA more profitable? Kiniksa Pharmaceuticals International has a net margin of 0.90% compared to Tyra Biosciences' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 1.05% beat Tyra Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International0.90% 1.05% 0.80% Tyra Biosciences N/A -31.22%-29.49% Do analysts recommend KNSA or TYRA? Kiniksa Pharmaceuticals International currently has a consensus target price of $41.17, indicating a potential upside of 16.22%. Tyra Biosciences has a consensus target price of $31.86, indicating a potential upside of 154.86%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Kiniksa Pharmaceuticals International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has higher valuation & earnings, KNSA or TYRA? Kiniksa Pharmaceuticals International has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M6.20-$43.19M$0.04885.50Tyra BiosciencesN/AN/A-$86.48M-$1.78-7.02 Does the media refer more to KNSA or TYRA? In the previous week, Kiniksa Pharmaceuticals International had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 9 mentions for Kiniksa Pharmaceuticals International and 4 mentions for Tyra Biosciences. Kiniksa Pharmaceuticals International's average media sentiment score of 1.11 beat Tyra Biosciences' score of 0.68 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in KNSA or TYRA? 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 15.2% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, KNSA or TYRA? Kiniksa Pharmaceuticals International has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. SummaryKiniksa Pharmaceuticals International beats Tyra Biosciences on 10 of the 15 factors compared between the two stocks. Get Tyra Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TYRA vs. The Competition Export to ExcelMetricTyra BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$681.67M$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-7.0220.5276.4826.75Price / SalesN/A446.54531.72124.23Price / CashN/A46.0037.9261.55Price / Book1.849.6613.726.40Net Income-$86.48M-$53.02M$3.29B$271.62M7 Day Performance-0.16%3.12%2.66%3.46%1 Month Performance22.07%7.57%6.02%9.87%1 Year Performance-48.69%11.17%80.02%28.45% Tyra Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TYRATyra Biosciences1.9733 of 5 stars$12.50-2.3%$31.86+154.9%-47.9%$681.67MN/A-7.0220KNSAKiniksa Pharmaceuticals International2.7098 of 5 stars$36.57+2.4%$41.17+12.6%+34.9%$2.65B$423.24M914.48220Positive NewsInsider TradeShort Interest ↑GMTXGemini TherapeuticsN/A$60.76+0.9%N/A+28.9%$2.63BN/A-60.7630News CoverageCGONCG Oncology2.613 of 5 stars$33.69+1.9%$53.91+60.0%-5.7%$2.52B$1.14M-19.0361Analyst ForecastAnalyst RevisionGap UpHigh Trading VolumeALVOAlvotech3.3557 of 5 stars$8.16-2.0%$14.00+71.6%-29.5%$2.51B$491.98M35.481,032News CoverageShort Interest ↓CPRXCatalyst Pharmaceuticals4.9232 of 5 stars$20.08-1.0%$33.20+65.3%-7.4%$2.48B$491.73M12.1780Positive NewsTARSTarsus Pharmaceuticals2.324 of 5 stars$56.89-1.3%$66.67+17.2%+59.0%$2.43B$182.95M-24.4250IDYAIDEAYA Biosciences3.9905 of 5 stars$23.39-13.9%$45.77+95.7%-27.0%$2.38B$7M-6.1780Analyst ForecastHigh Trading VolumeOCULOcular Therapeutix3.8865 of 5 stars$12.71-6.5%$17.20+35.3%+33.8%$2.37B$63.72M-9.93230Positive NewsGap UpMLYSMineralys Therapeutics2.5095 of 5 stars$35.93+3.2%$36.60+1.9%+224.5%$2.31BN/A-10.0928Insider TradeIBRXImmunityBio2.3465 of 5 stars$2.41+0.4%$10.75+346.1%-21.6%$2.27B$14.74M-5.02590 Related Companies and Tools Related Companies KNSA Alternatives GMTX Alternatives CGON Alternatives ALVO Alternatives CPRX Alternatives TARS Alternatives IDYA Alternatives OCUL Alternatives MLYS Alternatives IBRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TYRA) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TYRA Stock Alerts